Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.56 |
| ▸ | SELP | P16109 | 7/20 | 0.51 |
| ▸ | MAG | P20916 | 4/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.50 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30649207 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL29369094 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30649952 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30650122 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30651291 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30651920 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL31126371 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL29359311 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL20971391 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30650374 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371691-B2 | Nano complex for targeted repairing of neurovascular lesion, and preparation and use thereof | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2025-07-29 | — | — | US | claimed |
| CN-119971619-A | Synthesis system and synthesis process of monosialotetrahexosyl ganglioside GM1 | 武汉糖智药业有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119454898-A | Sedative maintenance medicament for oral mucosa administration and preparation method thereof | 佛山市口腔医院(佛山市牙病防治指导中心) | 2025-02-18 | — | — | CN | claimed |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| CN-118593449-A | Application of exosome in preparing medicine for treating nervous system diseases | 华悦汇(上海)健康科技有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-114931630-B | Ganglioside composition for subcutaneous injection and application thereof | 齐鲁制药有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20240287509-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2024-08-29 | — | — | US | claimed |
| CN-115243686-B | Use of butylphthalide and derivatives thereof | 石药集团恩必普药业有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117379448-A | Application of ganglioside GM1 in preparation of medicine for treating cerebral apoplexy | 齐鲁制药有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117357519-A | Application of MALT1 inhibitor in preparation of medicine for preventing and/or treating nerve function injury | 中国中医科学院中药研究所 | 2024-01-09 | — | — | CN | claimed |
| US-20230144023-A1 | USE OF BUTYLPHTHALIDE AND DERIVATIVE THEREOF | CSPC NBP PHARMACEUTICAL CO., LTD (CN) | 2023-05-11 | — | — | US | claimed |
| CN-114762679-B | Nano composite and preparation method and application thereof | 上海交通大学医学院 | 2023-04-07 | — | — | CN | claimed |
| EP-4122462-A1 | USE OF BUTYLPHTHALIDE AND DERIVATIVE THEREOF | CSPC NBP PHARMACEUTICAL CO., LTD. (CN) | 2023-01-25 | — | — | EP | claimed |
| CN-115463141-A | Use of ganglioside GM1 in medicine for treating hearing impairment | 齐鲁制药有限公司 | 2022-12-13 | — | — | CN | claimed |
| EP-4056168-A9 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-11-23 | — | — | EP | claimed |
| CN-115243686-A | Application of butylphthalide and derivatives thereof | 石药集团恩必普药业有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-114272268-B | Pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium and application thereof | 北京四环制药有限公司 | 2022-10-04 | — | — | CN | claimed |
| EP-4056168-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-09-14 | — | — | EP | claimed |
| CN-114762679-A | Nano composite and preparation method and application thereof | 上海交通大学医学院 | 2022-07-19 | — | — | CN | claimed |
| CN-114272268-A | Pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium and application thereof | 北京四环制药有限公司 | 2022-04-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | SIGLEC7 64/4885SELP 241/4885MAG 181/4885 |
| US-20230144023-A1 | USE OF BUTYLPHTHALIDE AND DERIVATIVE THEREOF | BAD, BBC3, PMP22 | SIGLEC7 4687/4885SELP 1930/4885MAG 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.